{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:54:32Z","timestamp":1773759272987,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1038\/ncpgasthep0092","type":"journal-article","created":{"date-parts":[[2005,2,15]],"date-time":"2005-02-15T16:00:10Z","timestamp":1108483210000},"page":"89-95","source":"Crossref","is-referenced-by-count":25,"title":["Drug Insight: appetite suppressants"],"prefix":"10.1038","volume":"2","author":[{"given":"George A","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpgasthep0092_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","volume":"20","author":"GA Bray","year":"1999","unstructured":"Bray GA and Greenway FL (1999) Current and potential drugs for treatment of obesity. Endocr Rev 20: 805\u2013875","journal-title":"Endocr Rev"},{"key":"BFncpgasthep0092_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/35007544","volume":"404","author":"GA Bray","year":"2000","unstructured":"Bray GA and Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404: 672\u2013677","journal-title":"Nature"},{"key":"BFncpgasthep0092_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK et al. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519\u2013526","journal-title":"Neuropsychopharmacology"},{"key":"BFncpgasthep0092_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/0024-3205(83)90008-5","volume":"33","author":"SL Sykas","year":"1983","unstructured":"Sykas SL et al. (1983) Anorectic drugs which stimulate thermogenesis. Life Sci 33: 1269\u20131275","journal-title":"Life Sci"},{"key":"BFncpgasthep0092_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/0091-3057(86)90378-3","volume":"25","author":"JR Lupien","year":"1986","unstructured":"Lupien JR and Bray GB (1986) Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Pharmacol Biochem Behav 25: 733\u2013738","journal-title":"Pharmacol Biochem Behav"},{"key":"BFncpgasthep0092_CR6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","volume":"68","author":"DL Hansen","year":"1998","unstructured":"Hansen DL et al. (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68: 1180\u20131186","journal-title":"Am J Clin Nutr"},{"key":"BFncpgasthep0092_CR7","first-page":"75","volume-title":"Obesity in Perspective","author":"BA Scoville","year":"1975","unstructured":"Scoville BA (1975) Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgments. In Obesity in Perspective. (Ed. Bray GA) Washington DC: Department of Health, Education, and Welfare Publication NIH 75\u2013708, 441\u2013443"},{"key":"BFncpgasthep0092_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro JF et al. (1968) Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1: 352\u2013354","journal-title":"Br Med J"},{"key":"BFncpgasthep0092_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","volume":"26","author":"CK Haddock","year":"2002","unstructured":"Haddock CK et al. (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26: 262\u2013273","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFncpgasthep0092_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R et al. (2003) Long-term pharmacotherapy for obesity and overweight: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437\u20131446","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFncpgasthep0092_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","volume":"7","author":"GA Bray","year":"1999","unstructured":"Bray GA et al. (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189\u2013198","journal-title":"Obes Res"},{"key":"BFncpgasthep0092_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WPT James","year":"2000","unstructured":"James WPT et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM study group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119\u20132125","journal-title":"Lancet"},{"key":"BFncpgasthep0092_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","volume":"286","author":"A Wirth","year":"2001","unstructured":"Wirth A and Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331\u20131339","journal-title":"JAMA"},{"key":"BFncpgasthep0092_CR14","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","volume":"160","author":"FG McMahon","year":"2000","unstructured":"McMahon FG et al. (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled multicenter trial. Arch Intern Med 160: 2185\u20132191","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep0092_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","volume":"16","author":"FG McMahon","year":"2002","unstructured":"McMahon FG et al. (2002) Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16: 5\u201311","journal-title":"J Hum Hypertens"},{"key":"BFncpgasthep0092_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000047310","volume":"94","author":"BP Hazenberg","year":"2000","unstructured":"Hazenberg BP (2000) Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94: 152\u2013158","journal-title":"Cardiology"},{"key":"BFncpgasthep0092_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.jhh.1001299","volume":"16","author":"JJ Sramek","year":"2002","unstructured":"Sramek, JJ et al. (2002) Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by \u03b2-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. J Hum Hypertens 16: 13\u201319","journal-title":"J Hum Hypertens"},{"key":"BFncpgasthep0092_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1001\/archinte.161.2.218","volume":"161","author":"RA Wadden","year":"2001","unstructured":"Wadden RA et al. (2001) Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 161: 218\u2013227","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep0092_CR19","first-page":"395","volume":"56","author":"JA Ascher","year":"1995","unstructured":"Ascher JA et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395\u2013401","journal-title":"J Clin Psychiatry"},{"key":"BFncpgasthep0092_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"JW Anderson","year":"2002","unstructured":"Anderson JW et al. (2002) Bupropion SR significantly enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10: 633\u2013641","journal-title":"Obes Res"},{"key":"BFncpgasthep0092_CR21","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(89)91499-2","volume":"2","author":"B Guy-Grand","year":"1989","unstructured":"Guy-Grand B et al. (1989) International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142\u20131145","journal-title":"Lancet"},{"key":"BFncpgasthep0092_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","volume":"144","author":"M Weintraub","year":"1984","unstructured":"Weintraub M et al. (1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144: 1143\u20131148","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep0092_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581\u2013588","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0092_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA et al. (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11: 722\u2013733","journal-title":"Obes Res"},{"key":"BFncpgasthep0092_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding J et al. (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28: 1399\u20131410","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFncpgasthep0092_CR26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","volume":"289","author":"KM Gadde","year":"2003","unstructured":"Gadde KM et al. (2003) Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289: 1820\u20131825","journal-title":"JAMA"},{"key":"BFncpgasthep0092_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/35071088","volume":"410","author":"V Di Marzo","year":"2001","unstructured":"Di Marzo V et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822\u2013825","journal-title":"Nature"},{"key":"BFncpgasthep0092_CR28","doi-asserted-by":"crossref","unstructured":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285: 2486\u20132497","DOI":"10.1001\/jama.285.19.2486"},{"key":"BFncpgasthep0092_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","volume":"13","author":"C Cohen","year":"2002","unstructured":"Cohen C et al. (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002 13: 451\u2013463","journal-title":"Behav Pharmacol"},{"key":"BFncpgasthep0092_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJM199909163411204","volume":"341","author":"IS Farooqi","year":"1999","unstructured":"Farooqi IS et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341: 879\u2013884","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0092_CR31","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1172\/JCI118007","volume":"95","author":"RV Considine","year":"1995","unstructured":"Considine RV et al. (1995) Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 95: 2986\u20132988","journal-title":"J Clin Invest"},{"key":"BFncpgasthep0092_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1301\/002966402320634878","volume":"60","author":"JM Friedman","year":"2002","unstructured":"Friedman JM (2002) The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (Part 2): S1\u2013S14","journal-title":"Nutr Rev"},{"issue":"Suppl 5","key":"BFncpgasthep0092_CR33","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1038\/sj.ijo.0801915","volume":"25","author":"MW Morton GJ and Schwartz","year":"2001","unstructured":"Morton GJ and Schwartz MW (2001) The NPY\/AgRP neuron and energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl 5): S56\u201362","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFncpgasthep0092_CR34","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB et al. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568\u20131575","journal-title":"JAMA"},{"key":"BFncpgasthep0092_CR35","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1073\/pnas.061034298","volume":"98","author":"PD Lambert","year":"2001","unstructured":"Lambert PD et al. (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Nat Acad Sci USA 98: 4652\u20134657","journal-title":"Proc Nat Acad Sci USA"},{"key":"BFncpgasthep0092_CR36","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jama.289.14.1826","volume":"289","author":"MP Ettinger","year":"2003","unstructured":"Ettinger MP et al. (2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826\u20131832","journal-title":"JAMA"},{"key":"BFncpgasthep0092_CR37","unstructured":"Regeneron Pharmaceuticals (online 14 April 2003) Regeneron's AXOKINE\u00ae promotes weight loss in study of overweight and obese people with type 2 diabetes [\n                    http:\/\/www.regeneron.com\/company\/press_detail.asp?v_c_id=170\n                    \n                  ] (accessed 23 December 2004)"},{"key":"BFncpgasthep0092_CR38","first-page":"163","volume":"53","author":"RD Palmiter","year":"1998","unstructured":"Palmiter RD et al. (1998) Life without neuropeptide Y. Recent Prog Horm Res 53: 163\u2013199","journal-title":"Recent Prog Horm Res"},{"key":"BFncpgasthep0092_CR39","first-page":"E627","volume":"274","author":"DS Ludwig","year":"1998","unstructured":"Ludwig DS et al. (1998) Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am J Physiol 274 (Part 1): E627\u2013E633","journal-title":"Am J Physiol"},{"key":"BFncpgasthep0092_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI10660","volume":"107","author":"DS Ludwig","year":"2001","unstructured":"Ludwig DS et al. (2001) Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379\u2013386","journal-title":"J Clin Invest"},{"key":"BFncpgasthep0092_CR41","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/25341","volume":"396","author":"M Shimada","year":"1998","unstructured":"Shimada M et al. (1998) Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670\u2013674","journal-title":"Nature"},{"key":"BFncpgasthep0092_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0092-8674(00)81865-6","volume":"88","author":"D Huszar","year":"1997","unstructured":"Huszar D et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131\u2013141","journal-title":"Cell"},{"key":"BFncpgasthep0092_CR43","first-page":"1144","volume":"86","author":"HL Fehm","year":"2001","unstructured":"Fehm HL et al. (2001) The melanocortin melanocyte-stimulating hormone\/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 86: 1144\u20131148","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0092","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:59:10Z","timestamp":1684439950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["BFncpgasthep0092"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0092","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}